blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3567030

EP3567030 - QUINAZOLINE COMPOUND FOR EGFR INHIBITION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.12.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  07.01.2022
FormerGrant of patent is intended
Status updated on  01.12.2021
FormerRequest for examination was made
Status updated on  12.11.2021
FormerGrant of patent is intended
Status updated on  10.08.2021
FormerRequest for examination was made
Status updated on  11.10.2019
FormerThe international publication has been made
Status updated on  07.07.2018
Most recent event   Tooltip27.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 30.10.2024  [2024/44]
Applicant(s)For all designated states
Medshine Discovery Inc.
Room 218, No.9 Gaoxin Road
Gaoxin Development District
Nanjing, Jiangsu 210032 / CN
[2019/46]
Inventor(s)01 / LIU, Xile
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
02 / DING, Charles Z.
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
03 / CHEN, Shuhui
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
04 / WU, Lingyun
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
05 / HU, Lihong
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
06 / WAN, Haiwen
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
 [2019/46]
Representative(s)Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte
Brucknerstraße 20
40593 Düsseldorf / DE
[2022/06]
Former [2019/46]Gille Hrabal
Brucknerstrasse 20
40593 Düsseldorf / DE
Application number, filing date17889371.529.12.2017
[2019/46]
WO2017CN119993
Priority number, dateCN20161125907130.12.2016         Original published format: CN201611259071
[2019/46]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018121758
Date:05.07.2018
Language:ZH
[2018/27]
Type: A1 Application with search report 
No.:EP3567030
Date:13.11.2019
Language:EN
[2019/46]
Type: B1 Patent specification 
No.:EP3567030
Date:09.02.2022
Language:EN
[2022/06]
Search report(s)International search report - published on:CN05.07.2018
(Supplementary) European search report - dispatched on:EP15.07.2020
ClassificationIPC:C07D239/86, C07D239/82, C07D239/94, C07D403/02, C07D403/14, A61K31/505
[2019/46]
CPC:
A61P35/00 (EP,CN,US); C07D498/10 (EP,CN,US); C07D498/04 (EP,US);
A61P35/04 (CN); C07D403/14 (US); C07D413/04 (EP);
C07D413/10 (US); C07D471/10 (EP); A61K45/06 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/46]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:CHINAZOLINVERBINDUNG ZUR EGFR-HEMMUNG[2019/46]
English:QUINAZOLINE COMPOUND FOR EGFR INHIBITION[2019/46]
French:COMPOSÉ QUINAZOLINE POUR L'INHIBITION DE L'EGFR[2019/46]
Entry into regional phase05.09.2019Translation filed 
05.09.2019National basic fee paid 
05.09.2019Search fee paid 
05.09.2019Designation fee(s) paid 
05.09.2019Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2019/46]
13.08.2019Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2019/46]
05.09.2019Examination requested  [2019/46]
15.02.2021Amendment by applicant (claims and/or description)
11.08.2021Communication of intention to grant the patent
10.11.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.11.2021Fee for grant paid
10.11.2021Fee for publishing/printing paid
09.12.2021Communication of intention to grant the patent
22.12.2021Receipt of the translation of the claim(s)
Opposition(s)10.11.2022No opposition filed within time limit [2023/03]
Request for further processing for:05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
04.12.2019Decision despatched
The application is deemed to be withdrawn due to failure to file the translation
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
The application is deemed to be withdrawn due to non-payment of the search fee
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
The application is deemed to be withdrawn due to non-payment of the filing fee
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
The application is deemed to be withdrawn due to non-payment of designation fees
TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
05.09.2019Request for further processing filed
05.09.2019Full payment received (date of receipt of payment)
Request granted
24.09.2019Decision despatched
Fees paidRenewal fee
29.11.2019Renewal fee patent year 03
26.11.2020Renewal fee patent year 04
30.11.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.12.2017
AL09.02.2022
AT09.02.2022
CY09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
MC09.02.2022
MK09.02.2022
MT09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
[2024/44]
Former [2024/29]HU29.12.2017
AL09.02.2022
AT09.02.2022
CY09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
MC09.02.2022
MK09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2024/27]HU29.12.2017
AL09.02.2022
AT09.02.2022
CY09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
MK09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2024/21]HU29.12.2017
AL09.02.2022
AT09.02.2022
CY09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2024/18]HU29.12.2017
AL09.02.2022
AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2023/35]AL09.02.2022
AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
IT09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2023/10]AL09.02.2022
AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SI09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2023/01]AL09.02.2022
AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/49]AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SK09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/48]AT09.02.2022
CZ09.02.2022
DK09.02.2022
EE09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/47]AT09.02.2022
DK09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RO09.02.2022
RS09.02.2022
SE09.02.2022
SM09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/46]AT09.02.2022
DK09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RS09.02.2022
SE09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/42]AT09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RS09.02.2022
SE09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
IS09.06.2022
PT09.06.2022
Former [2022/39]AT09.02.2022
ES09.02.2022
FI09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RS09.02.2022
SE09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
PT09.06.2022
Former [2022/36]AT09.02.2022
ES09.02.2022
HR09.02.2022
LT09.02.2022
LV09.02.2022
NL09.02.2022
PL09.02.2022
RS09.02.2022
SE09.02.2022
BG09.05.2022
NO09.05.2022
GR10.05.2022
PT09.06.2022
Former [2022/35]ES09.02.2022
HR09.02.2022
LT09.02.2022
NL09.02.2022
RS09.02.2022
SE09.02.2022
BG09.05.2022
NO09.05.2022
PT09.06.2022
Former [2022/34]ES09.02.2022
LT09.02.2022
NL09.02.2022
NO09.05.2022
PT09.06.2022
Former [2022/33]LT09.02.2022
NO09.05.2022
Documents cited:Search[XY]EP0566226  (ZENECA LTD [GB]) [X] 1-10,14,15 * abstract * * page 44; example 45 * * claim 1 * [Y] 1-10,12-15;
 [XY]EP0602851  (ZENECA LTD [GB]) [X] 1-10,14,15 * abstract * * page 13; example 6 * * claim 1 * [Y] 1-10,12-15;
 [XY]EP0635498  (ZENECA LTD [GB]) [X] 1-10,14,15 * abstract * * page 13; example 6 * * claim 1 * [Y] 1-10,12-15;
 [Y]WO2007059257  (ARRAY BIOPHARMA INC [US], et al) [Y] 1-10,12-15 * abstract * * page 127 - page 136; examples 120, 122, 146, 154, 180, 188 ** claim 1 *;
 [X]  - Shu Yu ET AL, "Early and Late Stage Process Development for the Manufacture of Dacomitinib", ACS Symposium Series, US, American Chemical Society/Oxford University Press, (20160101), vol. 1239, pages 235 - 252, doi:10.1021/bk-2016-1239.ch009, ISSN 0097-6156, XP055711842 [X] 1-10,14,15 * page 242; compound 28 *

DOI:   http://dx.doi.org/10.1021/bk-2016-1239.ch009
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.